Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.3390/ijms161125950 http://scihub22266oqcxt.onion/10.3390/ijms161125950 C4661809!4661809!26540039     free     free     free       Int+J+Mol+Sci 2015 ; 16 (11): 26077-86 Nephropedia Template TP {{tp|p=26540039|t=2015. Application of CRISPR/Cas9 Technology to HBV |pdf=|usr=}}{{26540039}} gab.com Text Application of CRISPR/Cas9 Technology to HBV JO: Int J Mol Sci http://www.kidney.de/pget.php?&tw=1&pmid=26540039 #FOAvip More than 240 million people around the world are chronically infected with hepatitis B virus (HBV). Nucleos(t)ide analogs and interferon are the only two families of drugs to treat HBV currently. However, none of these anti-virals directly target the stable nuclear covalently closed circular DNA (cccDNA), which acts as a transcription template for viral mRNA and pre-genomic RNA synthesis and secures virus persistence. Thus, the fact that only a small number of patients treated achieve sustained viral response (SVR) or cure, highlights the need for new therapies against HBV. The clustered regularly interspaced short palindromic repeats (CRISPR)/Cas9 gene editing system can specifically target the conserved regions of the HBV genome. This results in robust viral suppression and provides a promising tool for eradicating the virus. In this review, we discuss the function and application of the CRISPR/Cas9 system as a novel therapy for HBV. Twit Text FOAVip Application of CRISPR/Cas9 Technology to HBV ????Int J Mol Sci http://www.kidney.de/pget.php?&tw=1&pmid=26540039 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=26540039 #FOAvip English Wikipedia <ref>{{Cite pmid|26540039}}</ref> Application of CRISPR/Cas9 Technology to HBV #MMPMID26540039 Lin G; Zhang K; Li J Int J Mol Sci 2015[Nov]; 16 (11): 26077-86 PMID26540039show ga More than 240 million people around the world are chronically infected with hepatitis B virus (HBV). Nucleos(t)ide analogs and interferon are the only two families of drugs to treat HBV currently. However, none of these anti-virals directly target the stable nuclear covalently closed circular DNA (cccDNA), which acts as a transcription template for viral mRNA and pre-genomic RNA synthesis and secures virus persistence. Thus, the fact that only a small number of patients treated achieve sustained viral response (SVR) or cure, highlights the need for new therapies against HBV. The clustered regularly interspaced short palindromic repeats (CRISPR)/Cas9 gene editing system can specifically target the conserved regions of the HBV genome. This results in robust viral suppression and provides a promising tool for eradicating the virus. In this review, we discuss the function and application of the CRISPR/Cas9 system as a novel therapy for HBV. äApplication of CRISPR/Cas9 Technology to HBV (epmc).pdf DeepDyve Pubget Overpricing